ABVC BIOPHARMA, INC.
ABVC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABVC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABVC
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on in-licensing and conducting Phase I and II trials for drug and medical device candidates in CNS, Hematology/Oncology, and Ophthalmology, with a strategy to out-license post-Phase-II assets to larger pharmaceutical companies.
Key risk: Cash position and liquidity risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates for ABVC BIOPHARMA, INC..
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on in-licensing and conducting Phase I and II trials for drug and medical device candidates in CNS, Hematology/Oncology, and Ophthalmology, with a strategy to out-license post-Phase-II assets to larger pharmaceutical companies.
- ABVC focuses on Phase I and II clinical trials for investigational new drugs and medical devices in CNS, Hematology/Oncology, and Ophthalmology [sec · filed 2025-05-16].
- The company in-licenses candidates from large research institutes and universities in the U.S. and Taiwan [sec_mda · as of 2026-08-12].
- ABVC's business model is to out-license post-Phase-II products to pharmaceutical companies for further development and marketing [sec_mda · as of 2026-03-03].
- As of 2026-06-30, the company reported cash and equivalents of $0.0M, a net loss of -$0.7M, and total debt of $0.1M [sec].
- The company has not generated substantial revenue from its inception [sec_mda · as of 2025-04-15].
What works
- ABVC has in-licensed drug and medical device candidates from large research institutes and universities in both the U.S. and Taiwan, providing a pipeline of early-stage assets [sec_mda · as of 2026-08-12].
- The management team has extensive experience across new drug and medical device development [sec_mda · as of 2026-08-12].
- The company's strategy of out-licensing post-Phase-II products to pharmaceutical companies reduces the capital and risk burden of late-stage trials and commercialization [sec_mda · as of 2026-03-03].
What to weigh
- As of 2026-06-30, ABVC had cash and equivalents of $0.0M, indicating a lack of liquidity to fund operations without additional financing [sec].
- The company has not generated substantial revenue from its inception, highlighting a lack of commercial-stage products [sec_mda · as of 2025-04-15].
- The trading price of ABVC's common stock is likely to be highly volatile and subject to wide fluctuations, which could affect investor confidence [sec · filed 2025-05-16].
From the filings
Quoted directly from source documents.
ABVC focuses on Phase I and II trials in CNS, Hematology/Oncology, and Ophthalmology.
“We plan to augment our core research and development capability and assets by conducting Phase I and II clinical trials for investigational new drugs and medical devices in the fields of CNS, Hematology/Oncology and Ophthalmology.”
SEC filings · May 16, 2025
ABVC in-licenses candidates from large research institutes in the U.S. and Taiwan.
“we have in-licensed new drug and medical device candidates from large research institutes and universities in both the U.S. and Taiwan.”
SEC filings · August 12, 2026
ABVC's business model is to out-license post-Phase-II products.
“We primarily focus on Phase I and II research of new drug candidates and out license the post-Phase-II products to pharmaceutical companies”
SEC filings · August 12, 2026
ABVC has not generated substantial revenue from inception.
“From its inception, the Company has not generated substantial revenue from its medical device and new”
SEC MD&A · April 15, 2025
Risks & what to watch (3)›
Key risks
- Cash position and liquidity risk — As of 2026-06-30, cash and equivalents were $0.0M, indicating potential inability to fund operations without new financing [sec].
- No substantial revenue history — The company has not generated substantial revenue from its inception, reflecting a lack of approved or marketed products [sec_mda · as of 2025-04-15].
- Stock price volatility — The trading price of common stock is likely to be highly volatile and subject to wide fluctuations [sec · filed 2025-05-16].
What to watch
- Ability to secure additional financing given $0.0M cash as of 2026-06-30 [sec].
- Progress of Phase I and II clinical trials in CNS, Hematology/Oncology, and Ophthalmology [sec_mda · as of 2026-08-12].
- Any out-licensing agreements for post-Phase-II product candidates [sec_mda · as of 2026-03-03].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run ABVC BIOPHARMA, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ABVC BIOPHARMA, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.3 months
D/E 0.69 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$977K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 381,148 | $370K |
| geode capital management, llc | 221,169 | $215K |
| vanguard fiduciary trust co | 97,363 | $94K |
| renaissance technologies llc | 95,100 | $92K |
| state street corp | 72,800 | $71K |
| blackrock, inc. | 56,442 | $55K |
| northern trust corp | 32,087 | $31K |
| two sigma securities, llc | 21,023 | $20K |
| dimensional fund advisors lp | 12,227 | $12K |
| jane street group, llc | 10,700 | $10K |
Showing top 10 of 13 institutional holders of ABVC BIOPHARMA, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 29, 2026- % of float
- 1.4%
- Days to cover
- 2.4
- Shares short
- 295,274
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABVC short interestGovernance
Frequently asked questions
What is the AI investment thesis for ABVC BIOPHARMA, INC.?
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on in-licensing and conducting Phase I and II trials for drug and medical device candidates in CNS, Hematology/Oncology, and Ophthalmology, with a strategy to out-license post-Phase-II assets to larger pharmaceutical companies.
What is ABVC BIOPHARMA, INC.'s lead drug candidate?
ABVC BIOPHARMA, INC.'s most advanced tracked candidate is abv-1501 (Phase 2) for Triple Negative Breast Cancer (TNBC).
Who is the CEO of ABVC BIOPHARMA, INC.?
Dr. Uttam Yashwant Patil Ph.D. is the chief executive officer of ABVC BIOPHARMA, INC. (ABVC).
Where is ABVC BIOPHARMA, INC. headquartered?
ABVC BIOPHARMA, INC. (ABVC) is headquartered in Fremont, CA, United States.
What therapeutic areas does ABVC BIOPHARMA, INC. focus on?
ABVC BIOPHARMA, INC. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.